Poinsettia (300723): Short-term performance under pressure, R&D continues to advance
Incident: Yipinna released its 2023 annual report. In 2023, the company achieved operating revenue of 2.503 billion yuan, an increase of 9.79% over the previous year; realized net profit of 185 million yuan, a year-on-year decrease of 36.49%; achieved
Fosun Pharmaceuticals (600196): The first quarter met expectations and expected marginal improvement
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of 10.157 billion yuan, -7% YoY; attributed/deducted non-net profit of RMB610/609 million, respectively, or -38%/-34% YoY. Business
Express News | Hengrui launches GLP-1R/GIPR dual agonist weight loss phase III study
Solid Earnings Reflect Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Strength As A Business
Sichuan Biokin Pharmaceutical Co.,Ltd.'s (SHSE:688506) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shareholde
Xinhecheng (002001): Net profit attributable to 23 billion yuan decreased by 25.30% year-on-year, optimistic about the growth brought about by the commissioning of new projects
Shinwa Seong released its 2023 annual report. In 2023, the company achieved operating income of 15.117 billion yuan, a year-on-year decrease of 5.13%; realized net profit to mother of 2.704 billion yuan, a year-on-year decrease of 25.30%. 202
Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think
The market rallied behind Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) stock, leading do a rise in the share price after its recent weak earnings report. We think that shareholders might be